← All trials
NCT05245578
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 16, 2021
- Primary completion
- Nov 22, 2021
- Completion date
- Jan 12, 2022
- First posted
- Feb 18, 2022
- Last posted
- Feb 18, 2022
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PharmaEssentia Corp.Lead sponsor
- PharmaEssentia Corp.Collaborator
- Medical Corporation HOUEIKAI, Sekino Clinical Pharmacology ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.